## 4 Conclusions  
In the present study, tablets composed of 100% plant powder were formulated, and characterized, and in vitro kinetics dissolution was evaluated. Plant powders with a particle size between 100 and 500 \(\upmu\)m provide excellent-quality tablets after direct compression with a force of 14 kN. Unlike the classic approach to the administration of plant bioactive molecules, which consists of extracting the molecules and then incorporating them into pharmaceutical forms to be administered orally, the present study demonstrated the effectiveness of an innovative approach. This new approach involves the direct administration of plant powder in the form of tablets and allows the human body to extract the bioactive molecules using three extraordinary natural assets: the gastric environment (pH = 1.2), digestive enzymes produced by the human body, and digestion by intestinal microflora. These three conditions will effectively extract all the bioactive molecules contained in the plant matrix. The new approach will allow patients to be administered all bioactive molecules contained in the plant matrix in contrast to the conventional approach, which is based on extractable bioactive molecules only (Figure 7). From an economic point of view, this new approach is much more interesting because it saves the preparation fees of the extract (solvents, several unit operations, and very expensive processes) and the formulation fees (excipients and pharmaceutical operations). This original study is far from being complete; in vivo studies and clinical studies can be carried out to determine in detail the different proposed mechanisms concerning the fate of the plant powder after oral administration, namely, the effect of gastric juice on the plant matrix and the type of enzymes produced by the human body and plant matrix digestion mechanism by intestinal flora. This work can also serve as a basis for developing new pharmaceutical forms based on herbal powder and not extracts, such as improving the properties of tablets based on herbal powders by adding natural binders.  
Despite the promising technological and biopharmaceutical results obtained in this study, the findings should be considered preliminary. Several limitations must be acknowledged, particularly the absence of in vivo validation and the lack of detailed phytochemical characterization of the non-extractable polyphenic fraction. Further investigations, including pharmacokinetic, pharmacodynamic, and clinical studies, are necessary to confirm the efficacy and safety of this approach. Additionally, the development of this type of plant-based formulation may offer interesting economic and ecological benefits, especially through the valorization of natural resources and by-products. These aspects will be explored in future research aimed at fully establishing the relevance and feasibility of this innovative strategy.  
**Author Contributions:** Conceptualization, Y.N.B.; methodology, Y.N.B. and R.M.S.; software, N.Z.T. and M.S.; validation, R.F. and Y.N.B.; formal analysis, R.M.S.; investigation, D.G. and R.A.; resources, R.M.S. and R.F.; data curation, R.A.; writing--original draft preparation, M.S. and Y.N.B.; writing--review and editing, R.F.; visualization, R.M.S. and R.F.; supervision, Y.N.B.; project administration, Y.N.B.; funding acquisition, R.F. All authors have read and agreed to the published version of the manuscript.  
This research received no external funding.  
**Institutional Review Board Statement:** Not applicable.  
**Conflicts of Interest:** The authors declare no conflicts of interest.